Study
| A Phase II, Randomized, Open-label, multicenter trial |
| Progression under first-line treatment (except for immunotherapy) of dMMR/MSI metastatic colorectal cancer |
| Avelumab (n=65) vs SOC (n=67) |
Efficacy
| mOS: 25.8 vs. 23.4 mos, p=0.790 |
| mPFS: 4.1 vs. 6.2 mos, p=0.030 |
| 12 mos PFS: 31.2% vs 19.4% |
| 18 mos PFS: 27.4% vs. 9.1% |
| oRR: 29.5% vs 26.2% |
Safety
| Grade3: Liver enzyme increased (7.9% vs.1.6%), diarrhea (4.8% vs.7.8%), neutropenia (0 vs.18.8%), hypertension (1% vs 10.9%). |
JAMA Oncol, 3 AUG, 2023
http://doi.org/10.1001/jamaoncol.2023.2761
Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023
